[HTML][HTML] Clinical characterization of patients diagnosed with prostate cancer and undergoing conservative management: a PIONEER analysis based on big data
European Urology, 2024•Elsevier
Background Conservative management is an option for prostate cancer (PCa) patients
either with the objective of delaying or even avoiding curative therapy, or to wait until
palliative treatment is needed. PIONEER, funded by the European Commission Innovative
Medicines Initiative, aims at improving PCa care across Europe through the application of
big data analytics. Objective To describe the clinical characteristics and long-term outcomes
of PCa patients on conservative management by using an international large network of real …
either with the objective of delaying or even avoiding curative therapy, or to wait until
palliative treatment is needed. PIONEER, funded by the European Commission Innovative
Medicines Initiative, aims at improving PCa care across Europe through the application of
big data analytics. Objective To describe the clinical characteristics and long-term outcomes
of PCa patients on conservative management by using an international large network of real …
Background
Conservative management is an option for prostate cancer (PCa) patients either with the objective of delaying or even avoiding curative therapy, or to wait until palliative treatment is needed. PIONEER, funded by the European Commission Innovative Medicines Initiative, aims at improving PCa care across Europe through the application of big data analytics.
Objective
To describe the clinical characteristics and long-term outcomes of PCa patients on conservative management by using an international large network of real-world data.
Design, setting, and participants
From an initial cohort of >100 000 000 adult individuals included in eight databases evaluated during a virtual study-a-thon hosted by PIONEER, we identified newly diagnosed PCa cases (n = 527 311). Among those, we selected patients who did not receive curative or palliative treatment within 6 mo from diagnosis (n = 123 146).
Outcome measurements and statistical analysis
Patient and disease characteristics were reported. The number of patients who experienced the main study outcomes was quantified for each stratum and the overall cohort. Kaplan-Meier analyses were used to estimate the distribution of time to event data.
Results and limitations
The most common comorbidities were hypertension (35–73%), obesity (9.2–54%), and type 2 diabetes (11–28%). The rate of PCa-related symptomatic progression ranged between 2.6% and 6.2%. Hospitalization (12–25%) and emergency department visits (10–14%) were common events during the 1st year of follow-up. The probability of being free from both palliative and curative treatments decreased during follow-up. Limitations include a lack of information on patients and disease characteristics and on treatment intent.
Conclusions
Our results allow us to better understand the current landscape of patients with PCa managed with conservative treatment. PIONEER offers a unique opportunity to characterize the baseline features and outcomes of PCa patients managed conservatively using real-world data.
Patient summary
Up to 25% of men with prostate cancer (PCa) managed conservatively experienced hospitalization and emergency department visits within the 1st year after diagnosis; 6% experienced PCa-related symptoms. The probability of receiving therapies for PCa decreased according to time elapsed after the diagnosis.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果